News >

Expert Highlights Evolving Role of BMT in Hematologic Malignancies

Angelica Welch
Published: Friday, Apr 20, 2018

Koen van Besien, MD, PhD

Koen van Besien, MD, PhD
With the influx of novel therapeutics and the advent of chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies, bone marrow transplant (BMT) may seem to have been put on the back burner, says Koen van Besien, MD, PhD.

In an interview during the meeting, van Besien shared his insights on challenges with BMT and on the potential future for these technologies in a time when the landscape is undergoing many changes.

OncLive: Please provide an overview of your presentation.

van Besien: Transplant is a technology that spans across diseases. I talked about 3 different technologies: autologous transplant, CAR T cells, and allogeneic transplant. Each of these technologies has its indications and role in the management of certain diseases.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Multiple Myeloma: Changing Treatment Paradigms and the Emerging Potential of CAR T-Cell TherapyAug 30, 20191.5
2nd Annual Live Medical Crossfire®: Hematologic Malignancies OnlineSep 28, 20198.0
Publication Bottom Border
Border Publication